Plasma concentrations of P6 and PspC antibodies tended to be slightly lower in exacerbation-prone COPD patients than in stable COPD patients, but these differences were not statistically significant (Figure 2). This evidence concerns the gene SFTPC and chronic obstructive pulmonary disease.